![[Biolojic in StreetInsider] Aulos Bioscience presents poster on Phase 1/2 clinical trial of computationally designed IL-2 antibody AU-007 at 2022 ASCO annual meeting](https://blog.ourcrowd.com/wp-content/uploads/2018/03/streetinsider-logo.png "[Biolojic in StreetInsider] Aulos Bioscience presents poster on Phase 1/2 clinical trial of computationally designed IL-2 antibody AU-007 at 2022 ASCO annual meeting"){kind=logo}
[Biolojic in StreetInsider] Aulos Bioscience presents poster on Phase 1/2 clinical trial of computationally designed IL-2 antibody AU-007 at 2022 ASCO annual meeting
LARKSPUR, Calif.–(BUSINESS WIRE)– Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 ...